+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hemato Oncology Testing Market

  • PDF Icon

    Report

  • 118 Pages
  • December 2022
  • Region: Global
  • Polaris Market Research
  • ID: 5724177
The global hemato oncology testing market size is expected to reach USD 7,647.57 million by 2030, according to a new study. The report “Hemato Oncology Testing Market Share, Size, Trends, Industry Analysis Report, By Product & Service (Assay Kits and Services); By Cancer Type; Technology; By End-Use; By Region; Segment Forecast, 2022-2030” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Rising introduction to advanced molecular techniques by major companies to address various concerns pertaining to blood cancer prognosis and treatment courses along with the proliferation of advanced sequencing techniques like NGS are key factors influencing the market growth. Moreover, the increasing prevalence and incidence of many types of cancer and blood-related related diseases around the world are encouraging people to opt for hemato oncology tests for better treatment and diagnosis, which has been rising the growth of the market forward in recent years.

For instance, according to the World Health Organization, cancer is a leading cause of death globally accounting for around 10 million deaths in 2020, while the total number of cases estimated around the world was nearly 18.1 million, out of which 9.3 million cases were in men and 8.8 million in women. Similarly, around 900,000 people in the U.S. developed blood clots every year and accounting for around 100,000 casualties every year.

Moreover, the affordability of personalized therapy in cancer drugs and many other disease indications, high development of innovative drugs, fewer side-effects of personalized therapy, and high adoption in developed countries such as the United States, Canada, France, and Germany are also likely to influence the growth of the market and expected to contribute positively over the coming years. For instance, in august 2022, Medical Device Innovation Consortium introduced its somatic reference samples along with a pilot project to improve the validation and regulatory review process for the diagnostics of cancer based on NGS.

Hemato Oncology Testing Market Report Highlights

  • Services segment is expected to grow moderately in 2021 owing to a rapid rise in the incidence of non-Hodgkin among others.
  • Lymphoma segment dominated the global market in 2021, which is accelerated by the rapidly growing geriatric population.
  • NGS technology is expected to grow at a significant CAGR throughout the anticipated period on account of various advantages offered like sensitivity and specificity.
  • Hospitals segment held the largest market revenue share in 2021 due to the growing availability of specialized laboratory settings and heavily investing in the development of healthcare infrastructure.
  • Asia Pacific region is expected to witness the fastest growth throughout the anticipated period, which is mainly driven by rising R&D activities conducted by many large research institutes.
  • The global market key players include Abbott Laboratories, Roche, ARUP Diagnostics, Adaptive Biotechnologies, and Thermo Fisher Scientific.

The publisher has segmented the hemato oncology testing market report based on product & service, cancer type, technology, end-user, and region:

Hemato Oncology Testing, Product & Service Outlook (Revenue - USD Million, 2018 - 2030)

  • Assay Kits
  • Services

Hemato Oncology Testing, Cancer Type Outlook (Revenue - USD Million, 2018 - 2030)

  • Leukemia
  • Lymphoma
  • Others

Hemato Oncology Testing, Technology Outlook (Revenue - USD Million, 2018 - 2030)

  • PCR
  • IHC
  • NGS
  • Cytogenetics
  • Others

Hemato Oncology Testing, End-User Outlook (Revenue - USD Million, 2018 - 2030)

  • Clinical Laboratories
  • Hospitals
  • Academic & Research Institutes
  • Others

Hemato Oncology Testing, Regional Outlook (Revenue - USD Million, 2018 - 2030)

  • North America
  • U.S
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
Frequently Asked Questions about the Hemato Oncology Testing Market

What is the estimated value of the Hemato Oncology Testing Market?

The Hemato Oncology Testing Market was estimated to be valued at $2428.16 million in 2022.

What is the growth rate of the Hemato Oncology Testing Market?

The growth rate of the Hemato Oncology Testing Market is 15.4%, with an estimated value of $7647.57 million by 2030.

What is the forecasted size of the Hemato Oncology Testing Market?

The Hemato Oncology Testing Market is estimated to be worth $7647.57 million by 2030.

Who are the key companies in the Hemato Oncology Testing Market?

Key companies in the Hemato Oncology Testing Market include Abbott Laboratories, F. Hoffman, La Roche, QIAGEN, Thermo Fisher Scientific, Bio, Rad Laboratories, MolecularMD and ARUP Laboratories.

Table of Contents

1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary
2.1. Market Highlights

3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Sources
3.2.1. Primary Sources
3.2.2. Secondary Sources

4. Global Hemato Oncology Testing Market Insights
4.1. Hemato Oncology Testing - Industry Snapshot
4.2. Hemato Oncology Testing Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Availability of advanced molecular techniques for hemato-oncology diagnostics
4.2.1.2. Growing number of molecular decision support systems
4.2.2. Restraints and Challenges
4.2.2.1. Intellectual property rights protection issues
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTLE Analysis
4.5. Hemato Oncology Testing Industry Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. Global Hemato Oncology Testing Market, by Product & Service
5.1. Key Findings
5.2. Introduction
5.2.1. Global Hemato Oncology Testing Market, by Product & Service, 2018 - 2030 (USD Million)
5.3. Assay Kits
5.3.1. Global Hemato Oncology Testing Market, by Assay Kits, by Region, 2018 - 2030 (USD Million)
5.4. Services
5.4.1. Global Hemato Oncology Testing Market, by Services, by Region, 2018 - 2030 (USD Million)

6. Global Hemato Oncology Testing Market, by Technology
6.1. Key Findings
6.2. Introduction
6.2.1. Global Hemato Oncology Testing Market, by Technology, 2018 - 2030 (USD Million)
6.3. PCR
6.3.1. Global Hemato Oncology Testing Market, by PCR, by Region, 2018 - 2030 (USD Million)
6.4. IHC
6.4.1. Global Hemato Oncology Testing Market, by IHC, by Region, 2018 - 2030 (USD Million)
6.5. NGS
6.5.1. Global Hemato Oncology Testing Market, by NGS, by Region, 2018 - 2030 (USD Million)
6.6. Cytogenetics
6.6.1. Global Hemato Oncology Testing Market, by Cytogenetics, by Region, 2018 - 2030 (USD Million)
6.7. Others
6.7.1. Global Hemato Oncology Testing Market, by Others, by Region, 2018 - 2030 (USD Million)

7. Global Hemato Oncology Testing Market, by Cancer Type
7.1. Key Findings
7.2. Introduction
7.2.1. Global Hemato Oncology Testing Market, by Cancer Type, 2018 - 2030 (USD Million)
7.3. Leukemia
7.3.1. Global Hemato Oncology Testing Market, by Leukemia, by Region, 2018 - 2030 (USD Million)
7.4. Lymphoma
7.4.1. Global Hemato Oncology Testing Market, by Lymphoma, by Region, 2018 - 2030 (USD Million)
7.5. Others
7.5.1. Global Other Hemato Oncology Testing Market, by Region, 2018 - 2030 (USD Million)

8. Global Hemato Oncology Testing Market, by End-User
8.1. Key Findings
8.2. Introduction
8.2.1. Global Hemato Oncology Testing Market, by End-User, 2018 - 2030 (USD Million)
8.3. Clinical Laboratories
8.3.1. Global Hemato Oncology Testing Market, by Clinical Laboratories, by Region, 2018 - 2030 (USD Million)
8.4. Hospitals
8.4.1. Global Hemato Oncology Testing Market, by Hospitals, by Region, 2018 - 2030 (USD Million)
8.5. Academic & Research Institutes
8.5.1. Global Hemato Oncology Testing Market, by Academic & Research Institutes, by Region, 2018 - 2030 (USD Million)
8.6. Others
8.6.1. Global Other Hemato Oncology Testing Market, by Region, 2018 - 2030 (USD Million)

9. Global Hemato Oncology Testing Market, by Geography
9.1. Key findings
9.2. Introduction
9.2.1. Hemato Oncology Testing Market Assessment, By Geography, 2018 - 2030 (USD Million)
9.3. Hemato Oncology Testing Market - North America
9.3.1. North America: Hemato Oncology Testing Market, by Product & Service, 2018 - 2030 (USD Million)
9.3.2. North America: Hemato Oncology Testing Market, by End-User, 2018 - 2030 (USD Million)
9.3.3. North America: Hemato Oncology Testing Market, by Technology, 2018 - 2030 (USD Million)
9.3.4. North America: Hemato Oncology Testing Market, by Cancer Type, 2018 - 2030 (USD Million)
9.3.5. Hemato Oncology Testing Market - U.S.
9.3.5.1. U.S.: Hemato Oncology Testing Market, by Product & Service, 2018 - 2030 (USD Million)
9.3.5.2. U.S.: Hemato Oncology Testing Market, by End-User, 2018 - 2030 (USD Million)
9.3.5.3. U.S.: Hemato Oncology Testing Market, by Technology, 2018 - 2030 (USD Million)
9.3.5.4. U.S.: Hemato Oncology Testing Market, by Cancer Type, 2018 - 2030 (USD Million)
9.3.6. Hemato Oncology Testing Market - Canada
9.3.6.1. Canada: Hemato Oncology Testing Market, by Product & Service, 2018 - 2030 (USD Million)
9.3.6.2. Canada: Hemato Oncology Testing Market, by End-User, 2018 - 2030 (USD Million)
9.3.6.3. Canada: Hemato Oncology Testing Market, by Technology, 2018 - 2030 (USD Million)
9.3.6.4. Canada: Hemato Oncology Testing Market, by Cancer Type, 2018 - 2030 (USD Million)
9.4. Hemato Oncology Testing Market - Europe
9.4.1. Europe: Hemato Oncology Testing Market, by Product & Service, 2018 - 2030 (USD Million)
9.4.2. Europe: Hemato Oncology Testing Market, by End-User, 2018 - 2030 (USD Million)
9.4.3. Europe: Hemato Oncology Testing Market, by Technology, 2018 - 2030 (USD Million)
9.4.4. Europe: Hemato Oncology Testing Market, by Cancer Type, 2018 - 2030 (USD Million)
9.4.5. Hemato Oncology Testing Market - UK
9.4.5.1. UK: Hemato Oncology Testing Market, by Product & Service, 2018 - 2030 (USD Million)
9.4.5.2. UK: Hemato Oncology Testing Market, by End-User, 2018 - 2030 (USD Million)
9.4.5.3. UK: Hemato Oncology Testing Market, by Technology, 2018 - 2030 (USD Million)
9.4.5.4. UK: Hemato Oncology Testing Market, by Cancer Type, 2018 - 2030 (USD Million)
9.4.6. Hemato Oncology Testing Market - France
9.4.6.1. France: Hemato Oncology Testing Market, by Product & Service, 2018 - 2030 (USD Million)
9.4.6.2. France: Hemato Oncology Testing Market, by End-User, 2018 - 2030 (USD Million)
9.4.6.3. France: Hemato Oncology Testing Market, by Technology, 2018 - 2030 (USD Million)
9.4.6.4. France: Hemato Oncology Testing Market, by Cancer Type, 2018 - 2030 (USD Million)
9.4.7. Hemato Oncology Testing Market - Germany
9.4.7.1. Germany: Hemato Oncology Testing Market, by Product & Service, 2018 - 2030 (USD Million)
9.4.7.2. Germany: Hemato Oncology Testing Market, by End-User, 2018 - 2030 (USD Million)
9.4.7.3. Germany: Hemato Oncology Testing Market, by Technology, 2018 - 2030 (USD Million)
9.4.7.4. Germany: Hemato Oncology Testing Market, by Cancer Type, 2018 - 2030 (USD Million)
9.4.8. Hemato Oncology Testing Market - Italy
9.4.8.1. Italy: Hemato Oncology Testing Market, by Product & Service, 2018 - 2030 (USD Million)
9.4.8.2. Italy: Hemato Oncology Testing Market, by End-User, 2018 - 2030 (USD Million)
9.4.8.3. Italy: Hemato Oncology Testing Market, by Technology, 2018 - 2030 (USD Million)
9.4.8.4. Italy: Hemato Oncology Testing Market, by Cancer Type, 2018 - 2030 (USD Million)
9.4.9. Hemato Oncology Testing Market - Spain
9.4.9.1. Spain: Hemato Oncology Testing Market, by Product & Service, 2018 - 2030 (USD Million)
9.4.9.2. Spain: Hemato Oncology Testing Market, by End-User, 2018 - 2030 (USD Million)
9.4.9.3. Spain: Hemato Oncology Testing Market, by Technology, 2018 - 2030 (USD Million)
9.4.9.4. Spain: Hemato Oncology Testing Market, by Cancer Type, 2018 - 2030 (USD Million)
9.4.10. Hemato Oncology Testing Market - Netherlands
9.4.10.1. Netherlands: Hemato Oncology Testing Market, by Product & Service, 2018 - 2030 (USD Million)
9.4.10.2. Netherlands: Hemato Oncology Testing Market, by End-User, 2018 - 2030 (USD Million)
9.4.10.3. Netherlands: Hemato Oncology Testing Market, by Technology, 2018 - 2030 (USD Million)
9.4.10.4. Netherlands: Hemato Oncology Testing Market, by Cancer Type, 2018 - 2030 (USD Million)
9.4.11. Hemato Oncology Testing Market - Russia
9.4.11.1. Russia: Hemato Oncology Testing Market, by Product & Service, 2018 - 2030 (USD Million)
9.4.11.2. Russia.: Hemato Oncology Testing Market, by End-User, 2018 - 2030 (USD Million)
9.4.11.3. Russia: Hemato Oncology Testing Market, by Technology, 2018 - 2030 (USD Million)
9.4.11.4. Russia: Hemato Oncology Testing Market, by Cancer Type, 2018 - 2030 (USD Million)
9.5. Hemato Oncology Testing Market - Asia Pacific
9.5.1. Asia Pacific: Hemato Oncology Testing Market, by Product & Service, 2018 - 2030 (USD Million)
9.5.2. Asia Pacific: Hemato Oncology Testing Market, by End-User, 2018 - 2030 (USD Million)
9.5.3. Asia Pacific: Hemato Oncology Testing Market, by Technology, 2018 - 2030 (USD Million)
9.5.4. Asia Pacific: Hemato Oncology Testing Market, by Cancer Type, 2018 - 2030 (USD Million)
9.5.5. Hemato Oncology Testing Market - China
9.5.5.1. China: Hemato Oncology Testing Market, by Product & Service, 2018 - 2030 (USD Million)
9.5.5.2. China.: Hemato Oncology Testing Market, by End-User, 2018 - 2030 (USD Million)
9.5.5.3. China: Hemato Oncology Testing Market, by Technology, 2018 - 2030 (USD Million)
9.5.5.4. China: Hemato Oncology Testing Market, by Cancer Type, 2018 - 2030 (USD Million)
9.5.6. Hemato Oncology Testing Market - India
9.5.6.1. India: Hemato Oncology Testing Market, by Product & Service, 2018 - 2030 (USD Million)
9.5.6.2. India.: Hemato Oncology Testing Market, by End-User, 2018 - 2030 (USD Million)
9.5.6.3. India: Hemato Oncology Testing Market, by Technology, 2018 - 2030 (USD Million)
9.5.6.4. India: Hemato Oncology Testing Market, by Cancer Type, 2018 - 2030 (USD Million)
9.5.7. Hemato Oncology Testing Market - Japan
9.5.7.1. Japan: Hemato Oncology Testing Market, by Product & Service, 2018 - 2030 (USD Million)
9.5.7.2. Japan.: Hemato Oncology Testing Market, by End-User, 2018 - 2030 (USD Million)
9.5.7.3. Japan: Hemato Oncology Testing Market, by Technology, 2018 - 2030 (USD Million)
9.5.7.4. Japan: Hemato Oncology Testing Market, by Cancer Type, 2018 - 2030 (USD Million)
9.5.8. Hemato Oncology Testing Market - Malaysia
9.5.8.1. Malaysia: Hemato Oncology Testing Market, by Product & Service, 2018 - 2030 (USD Million)
9.5.8.2. Malaysia.: Hemato Oncology Testing Market, by End-User, 2018 - 2030 (USD Million)
9.5.8.3. Malaysia: Hemato Oncology Testing Market, by Technology, 2018 - 2030 (USD Million)
9.5.8.4. Malaysia: Hemato Oncology Testing Market, by Cancer Type, 2018 - 2030 (USD Million)
9.5.9. Hemato Oncology Testing Market - Indonesia
9.5.9.1. Indonesia: Hemato Oncology Testing Market, by Product & Service, 2018 - 2030 (USD Million)
9.5.9.2. Indonesia.: Hemato Oncology Testing Market, by End-User, 2018 - 2030 (USD Million)
9.5.9.3. Indonesia: Hemato Oncology Testing Market, by Technology, 2018 - 2030 (USD Million)
9.5.9.4. Indonesia: Hemato Oncology Testing Market, by Cancer Type, 2018 - 2030 (USD Million)
9.5.10. Hemato Oncology Testing Market - South Korea
9.5.10.1. South Korea: Hemato Oncology Testing Market, by Product & Service, 2018 - 2030 (USD Million)
9.5.10.2. South Korea.: Hemato Oncology Testing Market, by End-User, 2018 - 2030 (USD Million)
9.5.10.3. South Korea: Hemato Oncology Testing Market, by Technology, 2018 - 2030 (USD Million)
9.5.10.4. South Korea: Hemato Oncology Testing Market, by Cancer Type, 2018 - 2030 (USD Million)
9.6. Hemato Oncology Testing Market - Middle East & Africa
9.6.1. Middle East & Africa: Hemato Oncology Testing Market, by Product & Service, 2018 - 2030 (USD Million)
9.6.2. Middle East & Africa: Hemato Oncology Testing Market, by End-User, 2018 - 2030 (USD Million)
9.6.3. Middle East & Africa: Hemato Oncology Testing Market, by Technology, 2018 - 2030 (USD Million)
9.6.4. Middle East & Africa: Hemato Oncology Testing Market, by Cancer Type, 2018 - 2030 (USD Million)
9.6.5. Hemato Oncology Testing Market - Saudi Arabia
9.6.5.1. Saudi Arabia: Hemato Oncology Testing Market, by Product & Service, 2018 - 2030 (USD Million)
9.6.5.2. Saudi Arabia: Hemato Oncology Testing Market, by End-User, 2018 - 2030 (USD Million)
9.6.5.3. Saudi Arabia: Hemato Oncology Testing Market, by Technology, 2018 - 2030 (USD Million)
9.6.5.4. Saudi Arabia: Hemato Oncology Testing Market, by Cancer Type, 2018 - 2030 (USD Million)
9.6.6. Hemato Oncology Testing Market - South Africa
9.6.6.1. South Africa: Hemato Oncology Testing Market, by Product & Service, 2018 - 2030 (USD Million)
9.6.6.2. South Africa: Hemato Oncology Testing Market, by End-User, 2018 - 2030 (USD Million)
9.6.6.3. South Africa: Hemato Oncology Testing Market, by Technology, 2018 - 2030 (USD Million)
9.6.6.4. South Africa: Hemato Oncology Testing Market, by Cancer Type, 2018 - 2030 (USD Million)
9.6.7. Hemato Oncology Testing Market - Israel
9.6.7.1. Israel: Hemato Oncology Testing Market, by Product & Service, 2018 - 2030 (USD Million)
9.6.7.2. Israel: Hemato Oncology Testing Market, by End-User, 2018 - 2030 (USD Million)
9.6.7.3. Israel: Hemato Oncology Testing Market, by Technology, 2018 - 2030 (USD Million)
9.6.7.4. Israel: Hemato Oncology Testing Market, by Cancer Type, 2018 - 2030 (USD Million)
9.6.8. Hemato Oncology Testing Market - UAE
9.6.8.1. UAE: Hemato Oncology Testing Market, by Product & Service, 2018 - 2030 (USD Million)
9.6.8.2. UAE: Hemato Oncology Testing Market, by End-User, 2018 - 2030 (USD Million)
9.6.8.3. UAE: Hemato Oncology Testing Market, by Technology, 2018 - 2030 (USD Million)
9.6.8.4. UAE: Hemato Oncology Testing Market, by Cancer Type, 2018 - 2030 (USD Million)
9.7. Hemato Oncology Testing Market - Latin America
9.7.1. Latin America: Hemato Oncology Testing Market, by Product & Service, 2018 - 2030 (USD Million)
9.7.2. Latin America: Hemato Oncology Testing Market, by End-User, 2018 - 2030 (USD Million)
9.7.3. Latin America: Hemato Oncology Testing Market, by Technology, 2018 - 2030 (USD Million)
9.7.4. Latin America: Hemato Oncology Testing Market, by Cancer Type, 2018 - 2030 (USD Million)
9.7.5. Hemato Oncology Testing Market - Mexico
9.7.5.1. Mexico: Hemato Oncology Testing Market, by Product & Service, 2018 - 2030 (USD Million)
9.7.5.2. Mexico: Hemato Oncology Testing Market, by End-User, 2018 - 2030 (USD Million)
9.7.5.3. Mexico: Hemato Oncology Testing Market, by Technology, 2018 - 2030 (USD Million)
9.7.5.4. Mexico: Hemato Oncology Testing Market, by Cancer Type, 2018 - 2030 (USD Million)
9.7.6. Hemato Oncology Testing Market - Brazil
9.7.6.1. Brazil: Hemato Oncology Testing Market, by Product & Service, 2018 - 2030 (USD Million)
9.7.6.2. Brazil: Hemato Oncology Testing Market, by End-User, 2018 - 2030 (USD Million)
9.7.6.3. Brazil: Hemato Oncology Testing Market, by Technology, 2018 - 2030 (USD Million)
9.7.6.4. Brazil: Hemato Oncology Testing Market, by Cancer Type, 2018 - 2030 (USD Million)
9.7.7. Hemato Oncology Testing Market - Argentina
9.7.7.1. Argentina: Hemato Oncology Testing Market, by Product & Service, 2018 - 2030 (USD Million)
9.7.7.2. Argentina: Hemato Oncology Testing Market, by End-User, 2018 - 2030 (USD Million)
9.7.7.3. Argentina: Hemato Oncology Testing Market, by Technology, 2018 - 2030 (USD Million)
9.7.7.4. Argentina: Hemato Oncology Testing Market, by Cancer Type, 2018 - 2030 (USD Million)

10. Competitive Landscape
10.1. Expansion and Acquisition Analysis
10.1.1. Expansion
10.1.2. Acquisitions
10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles
11.1. Abbott Laboratories
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Benchmarking
11.1.4. Recent Development
11.2. F. Hoffman-La Roche
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Benchmarking
11.2.4. Recent Development
11.3. QIAGEN
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Benchmarking
11.3.4. Recent Development
11.4. Thermo Fisher Scientific
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Benchmarking
11.4.4. Recent Development
11.5. Bio-Rad Laboratories
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Benchmarking
11.5.4. Recent Development
11.6. MolecularMD
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Benchmarking
11.6.4. Recent Development
11.7. ArcherDX
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Benchmarking
11.7.4. Recent Development
11.8. ARUP Laboratories
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Benchmarking
11.8.4. Recent Development
11.9. Adaptive Biotechnologies
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Benchmarking
11.9.4. Recent Development
11.10. Amoy Diagnostics
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Benchmarking
11.10.4. Recent Development
11.11. Vela Diagnostics
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Benchmarking
11.11.4. Recent Development
11.12. SAGA Diagnostics
11.12.1. Company Overview
11.12.2. Financial Performance
11.12.3. Product Benchmarking
11.12.4. Recent Development
11.13. Olink
11.13.1. Company Overview
11.13.2. Financial Performance
11.13.3. Product Benchmarking
11.13.4. Recent Development
11.14. Gentronix
11.14.1. Company Overview
11.14.2. Financial Performance
11.14.3. Product Benchmarking
11.14.4. Recent Development
11.15. Asuragen
11.15.1. Company Overview
11.15.2. Financial Performance
11.15.3. Product Benchmarking
11.15.4. Recent Development
11.16. Illumina Inc
11.16.1. Company Overview
11.16.2. Financial Performance
11.16.3. Product Benchmarking
11.16.4. Recent Development

Companies Mentioned

  • Abbott Laboratories
  • F. Hoffman-La Roche
  • QIAGEN
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories
  • MolecularMD
  • ArcherDX
  • ARUP Laboratories
  • Adaptive Biotechnologies
  • Amoy Diagnostics
  • Vela Diagnostics
  • SAGA Diagnostics
  • Olink
  • Gentronix
  • Asuragen
  • Illumina Inc.